Kidney tumours - Revision history

Michael at 20:49, 29 November 2024

2024-11-29T20:49:01Z

← Older revision		Revision as of 20:49, 29 November 2024
Line 237:		Line 237:
	*[[ALK translocation renal cell carcinoma]].		*[[ALK translocation renal cell carcinoma]].

	==~~An entity~~ proposed after Vancouver==		==Entities proposed after Vancouver==
	*[[Eosinophilic, solid and cystic renal cell carcinoma]].		*[[Eosinophilic, solid and cystic renal cell carcinoma]] - part of 2022 WHO Classification.
	*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].		*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].
	*[[Papillary renal neoplasm with reverse polarity]].		*[[Papillary renal neoplasm with reverse polarity]].

Michael at 21:41, 15 August 2024

2024-08-15T21:41:08Z

← Older revision		Revision as of 21:41, 15 August 2024
Line 351:		Line 351:
	{{Main\|Chromophobe renal cell carcinoma}}		{{Main\|Chromophobe renal cell carcinoma}}

	==Clear cell papillary renal cell ~~carcinoma~~==		==Clear cell papillary renal cell tumour==
	{{Main\|Clear cell papillary renal cell ~~carcinoma~~}}		In the past, it was known as ''clear cell papillary renal cell carcinoma''.
			{{Main\|Clear cell papillary renal cell tumour}}

	==Unclassified renal cell carcinoma==		==Unclassified renal cell carcinoma==

Michael at 21:37, 15 August 2024

2024-08-15T21:37:21Z

← Older revision		Revision as of 21:37, 15 August 2024
Line 328:		Line 328:

	==Hereditary renal cell carcinoma==		==Hereditary renal cell carcinoma==
	~~The classics - which are ''all'' autosomal dominant:<ref name=Ref_PBoD1016>~~{{~~Ref PBoD~~\|~~1016}}</ref>~~		{{Main\|Hereditary renal cell carcinoma}}
	~~# [[Von Hippel-Lindau syndrome]].~~
	~~#* VHL gene mutation.~~
	~~#* Clear cell RCC.~~
	~~# Hereditary [[clear cell renal cell carcinoma]].~~
	~~#* VHL gene mutation.~~
	~~# Hereditary [[papillary renal cell carcinoma]].~~
	~~#* MET proto-oncogene mutation.~~
	~~#* PaRCC type 1.<ref name=Ref_WMSP290>{{Ref WMSP\|290}}</ref>~~
	~~# [[~~Hereditary ~~leiomyomatosis and~~ renal cell ~~cancer]]:<ref name=Ref_WMSP290>{{Ref WMSP\|290}}</ref>~~
	~~#* FH (fumarate hydratase) gene mutation.<ref name=omim136850>{{OMIM\|136850}}</ref>~~
	~~#* PaRCC type 2.~~
	~~#* Benign [[leiomyoma]]s skin/[[uterine leiomyoma\|uterus]].~~
	~~#* Uterine [[leiomyosarcoma]].~~
	~~# [[Birt–Hogg–Dubé syndrome]]:<ref name=Ref_WMSP290>{{Ref WMSP\|290}}</ref>~~
	~~#* FLCN (folliculin) gene mutation.<ref name=omim135150>{{OMIM\|135150}}</ref>~~
	~~#* Skin lesions (fibrofolliculoma, trichodiscoma, [[acrochordon]]).~~
	~~#* ChRCC most common, other types seen (e.g. [[renal oncocytoma\|oncocytoma]]).~~
	~~#* Variable penetrance (autosomal dominant).~~

	~~Others:~~
	* Hereditary papillary carcinoma ~~(TFE3 related translocations).<ref name=omim314310>{{OMIM\|314310}}</ref>~~

	~~Notes:<br>~~
	*A total of ten hereditary renal cancer syndromes have been described. In eight of the ten the gene is known.<ref name=pmid20817385>{{Cite journal \| last1 = Verine \| first1 = J. \| last2 = Pluvinage \| first2 = A. \| last3 = Bousquet \| first3 = G. \| last4 = Lehmann-Che \| first4 = J. \| last5 = de Bazelaire \| first5 = C. \| last6 = Soufir \| first6 = N. \| last7 = Mongiat-Artus \| first7 = P. \| title = Hereditary renal cancer syndromes: an update of a systematic review. \| journal = Eur Urol \| volume = 58 \| issue = 5 \| pages = 701-10 \| month = Nov \| year = 2010 \| doi = 10.1016/j.eururo.2010.08.031 \| PMID = 20817385 }}</ref>

	~~===Molecular===~~
	~~Recurrent molecular changes in RCC:~~
	*Clear cell RCC:
	**Loss of 3p - contains the VHL gene.
	*Papillary RCC:
	**Sporadic:
	***Trisomy 7, 16, 17.
	***Loss of Y.
	**Familial:
	***Trisomy 7 - contains MET gene.<ref>{{OMIM\|164860}}~~</ref>~~

	==Renal cell carcinoma grading==		==Renal cell carcinoma grading==

Michael: /* An entity proposed after Vancouver */

2021-10-13T02:48:57Z

An entity proposed after Vancouver

← Older revision		Revision as of 02:48, 13 October 2021
Line 241:		Line 241:
	*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].		*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].
	*[[Papillary renal neoplasm with reverse polarity]].		*[[Papillary renal neoplasm with reverse polarity]].
			*[[Low-grade oncocytic renal tumour]].

	=Renal cell carcinoma=		=Renal cell carcinoma=

Michael: /* An entity proposed after Vancouver */ one more

2021-10-13T02:46:47Z

An entity proposed after Vancouver: one more

← Older revision		Revision as of 02:46, 13 October 2021
Line 240:		Line 240:
	*[[Eosinophilic, solid and cystic renal cell carcinoma]].		*[[Eosinophilic, solid and cystic renal cell carcinoma]].
	*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].		*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].
			*[[Papillary renal neoplasm with reverse polarity]].

	=Renal cell carcinoma=		=Renal cell carcinoma=

Michael: /* An entity proposed after Vancouver */

2021-10-13T02:43:48Z

An entity proposed after Vancouver

← Older revision		Revision as of 02:43, 13 October 2021
Line 239:		Line 239:
	==An entity proposed after Vancouver==		==An entity proposed after Vancouver==
	*[[Eosinophilic, solid and cystic renal cell carcinoma]].		*[[Eosinophilic, solid and cystic renal cell carcinoma]].
			*[[Biphasic hyalinizing psammomatous renal cell carcinoma]].

	=Renal cell carcinoma=		=Renal cell carcinoma=

Michael: /* Risk factors */

2018-11-29T17:28:33Z

Risk factors

← Older revision		Revision as of 17:28, 29 November 2018
Line 264:		Line 264:
	*Male>female (~2:1).		*Male>female (~2:1).
	*Hereditary - familial syndromes (see [[Hereditary RCC]]).		*Hereditary - familial syndromes (see [[Hereditary RCC]]).
			*[[Obesity]].<ref name=pmid8770461>{{Cite journal \| last1 = Chow \| first1 = WH. \| last2 = McLaughlin \| first2 = JK. \| last3 = Mandel \| first3 = JS. \| last4 = Wacholder \| first4 = S. \| last5 = Niwa \| first5 = S. \| last6 = Fraumeni \| first6 = JF. \| title = Obesity and risk of renal cell cancer. \| journal = Cancer Epidemiol Biomarkers Prev \| volume = 5 \| issue = 1 \| pages = 17-21 \| month = Jan \| year = 1996 \| doi = \| PMID = 8770461 }}</ref>

	===Subtypes of RCC===		===Subtypes of RCC===

Michael: /* Missed renal biopsy */

2017-01-05T20:28:20Z

Missed renal biopsy

← Older revision		Revision as of 20:28, 5 January 2017
Line 23:		Line 23:
	===Sign out===		===Sign out===
	====Missed renal biopsy====		====Missed renal biopsy====
	~~<pre>~~		{{Main\|Missed renal biopsy}}
	~~KIDNEY (LESION), LEFT, CORE BIOPSY:~~
	~~- RENAL PARENCHYMA.~~
	~~- NEGATIVE FOR MASS LESION, SEE COMMENT.~~

	~~COMMENT:~~
	~~No mass lesion is apparent in the tissue sampled. A re-~~biopsy ~~should be considered.~~

	~~Renal parenchyma:~~
	~~- Glomeruli: seven glomeruli sampled, no apparent glomerular pathology on the H&E sections.~~
	~~- Interstitium: interstitial fibrosis is not identified.~~
	~~- Tubules: no pathology is apparent.~~
	~~- Vessels: mild atherosclerosis, no hyalinization of arterioles apparent.~~
	~~</pre>~~

	=Tabular comparison (selected tumours)=		=Tabular comparison (selected tumours)=

Michael: /* Renal cell carcinoma grading */ split out

2016-05-26T16:45:48Z

Renal cell carcinoma grading: split out

← Older revision		Revision as of 16:45, 26 May 2016
Line 375:		Line 375:

	==Renal cell carcinoma grading==		==Renal cell carcinoma grading==
	~~===General===~~		{{Main\|Renal cell carcinoma grading}}
	~~There are two systems:~~
	*''Fuhrman grading'':
	**Older and more complicated.
	**Based on nuclear size and shape, chromatin pattern and [[nucleoli\|nucleolar size]].<ref name=Ref_GUP282>{{Ref GUP\|282}}</ref>
	*''[[ISUP]] grading'':<ref name=pmid24025520>{{cite journal \|author=Delahunt B, Cheville JC, Martignoni G, ''et al.'' \|title=The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters \|journal=Am. J. Surg. Pathol. \|volume=37 \|issue=10 \|pages=1490–504 \|year=2013 \|month=October \|pmid=24025520 \|doi=10.1097/PAS.0b013e318299f0fb \|url=}}</ref>
	**Newer and less complicated.
	**Mostly based on [[nucleoli\|nucleolar size]] and to a much lesser degree on size and morphology
	**Developed based on ''Fuhrman grading''.

	~~===ISUP grading===~~
	~~Criteria:<ref name=pmid24025520/>~~
	*Grade 1 - nucleoli absent/very small at 400x. §
	*Grade 2 - nucleoli seen with 400x, but not at 100x. §§
	*Grade 3 - nucleoli seen at 100x, i.e. with the 10x objective.
	*Grade 4 - extreme nuclear pleomorphism (esp. nuclear enlargement) ''or'' [[renal cell carcinoma with sarcomatoid differentiation\|sarcomatoid differentiation]] ([[spindle cell]]s<ref name=pmid15763002>{{Cite journal \| last1 = Dall'Oglio \| first1 = MF. \| last2 = Lieberknecht \| first2 = M. \| last3 = Gouveia \| first3 = V. \| last4 = Sant'Anna \| first4 = AC. \| last5 = Leite \| first5 = KR. \| last6 = Srougi \| first6 = M. \| title = Sarcomatoid differentiation in renal cell carcinoma: prognostic implications. \| journal = Int Braz J Urol \| volume = 31 \| issue = 1 \| pages = 10-6 \| month = \| year = \| doi = \| PMID = 15763002 }}</ref> or [[Renal cell carcinoma ~~with rhabdoid morphology\|rhabdoid cells]]).~~

	~~Cavets:<ref name=pmid24025520/>~~
	*Higher grade component trumps lower grade component.
	**No agreed upon minimum quantity of high grade component for upgrading.
	***37% use 1 field of view with the x10 objective. †
	***41% use 1 field of view with the x40 objective. ‡
	*Grading system ''not'' used for ''[[chromophobe RCC]]''.
	**The experience with the ''Fuhrman grading'' system showed it is ''not'' prognostic for chromophobe RCC.<ref name=pmid17527087>{{Cite journal \| last1 = Delahunt \| first1 = B. \| last2 = Sika-Paotonu \| first2 = D. \| last3 = Bethwaite \| first3 = PB. \| last4 = McCredie \| first4 = MR. \| last5 = Martignoni \| first5 = G. \| last6 = Eble \| first6 = JN. \| last7 = Jordan \| first7 = TW. \| title = Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. \| journal = Am J Surg Pathol \| volume = 31 \| issue = 6 \| pages = 957-60 \| month = Jun \| year = 2007 \| doi = 10.1097/01.pas.0000249446.28713.53 \| PMID = 17527087 }}</ref>

	~~Notes:~~
	*† Suffers from [[IPFitis]].
	*‡ Suffers from [[HPFitis]].
	*§ Some describe Grade 1 nuclei as ''lymphocyte-like''.{{fact}}
	*§§ Some suggest the following relationship between grading/nucleoli:{{fact}}
	**Grade 1 = nucleoli seen at 400x.
	**Grade 2 = nucleoli seen at 200x.
	**Grade 3 = nucleoli seen at 100x.

	==Renal cell carcinoma staging==		==Renal cell carcinoma staging==

Michael: /* Vancouver modification of WHO classification */

2016-02-26T21:08:58Z

Vancouver modification of WHO classification

← Older revision		Revision as of 21:08, 26 February 2016
Line 250:		Line 250:
	*[[ALK translocation renal cell carcinoma]].		*[[ALK translocation renal cell carcinoma]].

	An entity proposed after Vancouver:		==An entity proposed after Vancouver==
	*[[Eosinophilic, solid and cystic renal cell carcinoma]].		*[[Eosinophilic, solid and cystic renal cell carcinoma]].